These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25376000)

  • 1. Ticagrelor for the treatment of peripheral arterial disease.
    Chong AY; So DY
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1737-43. PubMed ID: 25376000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ticagrelor for the treatment of arterial thrombosis.
    Gurbel PA; Kereiakes DJ; Tantry US
    Expert Opin Pharmacother; 2010 Sep; 11(13):2251-9. PubMed ID: 20707759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor: a novel oral antiplatelet agent.
    Huang NS; Master HH; Fusco JA; Park ZH
    Consult Pharm; 2010 Nov; 25(11):745-55. PubMed ID: 21138823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New antiplatelet agents in the treatment of acute coronary syndromes.
    Sabouret P; Taiel-Sartral M
    Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ideal antiplatelet therapy for coronary artery disease: focus on adenosine diphosphate receptor inhibitors.
    Chandrasekar S; Loomba R; Shah P; Arora R
    Am J Ther; 2013; 20(4):337-43. PubMed ID: 21519219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.
    Teng R
    Clin Pharmacokinet; 2012 May; 51(5):305-18. PubMed ID: 22489610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor in modern cardiology - an up-to-date review of most important aspects of ticagrelor pharmacotherapy.
    Danielak D; Karaźniewicz-Łada M; Główka F
    Expert Opin Pharmacother; 2018 Feb; 19(2):103-112. PubMed ID: 29280403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.
    Cheng JW
    Clin Ther; 2012 Jun; 34(6):1209-20. PubMed ID: 22521881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ticagrelor: from discovery to Phase III clinical trial.
    Siller-Matula JM; Jilma B
    Future Cardiol; 2010 Nov; 6(6):753-64. PubMed ID: 21142630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor: positive, negative and misunderstood properties as a new antiplatelet agent.
    Steiner JB; Wu Z; Ren J
    Clin Exp Pharmacol Physiol; 2013 Jul; 40(7):398-403. PubMed ID: 23590223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor: the first novel reversible P2Y(12) inhibitor.
    Htun WW; Steinhubl SR
    Expert Opin Pharmacother; 2013 Feb; 14(2):237-45. PubMed ID: 23268703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.
    Hiatt WR; Fowkes FG; Heizer G; Berger JS; Baumgartner I; Held P; Katona BG; Mahaffey KW; Norgren L; Jones WS; Blomster J; Millegård M; Reist C; Patel MR;
    N Engl J Med; 2017 Jan; 376(1):32-40. PubMed ID: 27959717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fresh from the pipeline. Ticagrelor.
    Huber K; Hamad B; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Apr; 10(4):255-6. PubMed ID: 21455230
    [No Abstract]   [Full Text] [Related]  

  • 14. Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
    Gaglia MA; Waksman R
    Circulation; 2011 Feb; 123(4):451-6. PubMed ID: 21242480
    [No Abstract]   [Full Text] [Related]  

  • 15. Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease.
    Nicolau JC; Baracioli LM; Giugliano RP
    Expert Opin Pharmacother; 2018 Jun; 19(9):1013-1019. PubMed ID: 29893152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
    Torngren K; Ohman J; Salmi H; Larsson J; Erlinge D
    Cardiology; 2013; 124(4):252-8. PubMed ID: 23594617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
    Oprea AD; Popescu WM
    J Cardiothorac Vasc Anesth; 2013 Aug; 27(4):779-95. PubMed ID: 23648080
    [No Abstract]   [Full Text] [Related]  

  • 18. Ticagrelor. Acute coronary syndromes: nothing new.
    Prescrire Int; 2011 Oct; 20(120):229-33. PubMed ID: 21970081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.
    Monitillo F; Iacoviello M; Caldarola P; Valle R; Chiatto M; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):977-93. PubMed ID: 25882759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor in ST-elevation myocardial infarction.
    Sgueglia GA; Tarantini G; Niccoli G
    Curr Vasc Pharmacol; 2012 Jul; 10(4):458-62. PubMed ID: 22339257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.